Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
Crossref DOI link: https://doi.org/10.1007/s12094-014-1210-x
Published Online: 2014-08-14
Published Print: 2015-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Salvador, J.
Manso, L.
de la Haba, J.
Jaen, A.
Ciruelos, E.
de Villena, M. C.
Gil, M.
Murias, A.
Galan, A.
Jara, C.
Bayo, J.
Baena, J. M.
Casal, J.
Mel, J. R.
Blancas, I.
Sanchez Rvira, P.
Text and Data Mining valid from 2014-08-14